This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
=== Kripik tempe === Kripik tempe snack crackers; a thinly sliced tempeh, battered and deep fried until crispy. It is popular across Java, but notably produced in Bandung, West Java and Malang, East Java.
== Brigade Commanders == 2003 - 2005 : Général Jean-Paul Thonier 2005 - 2007 : Général Hervé Charpentier 2007 - 2009 : Général Éric Bonnemaison 2009 - 2011 : Général Jean-François Hogard 2011 - 2013 : Général François Lecointre 2013 - 2015 : Général Vincent Guionie 2015 - 201x :: Général François Labuze
pyrimidine Abbreviated in shorthand with the letter Y. A single-ringed heterocyclic organic compound which, along with purine, is one of two molecules from which all nitrogenous bases (including the nucleobases used in DNA and RNA) are derived. Cytosine (C), thymine (T), and uracil (U) are classified as pyrimidines. The letter Y is sometimes used to indicate a generic pyrimidine; e.g. in a nucleotide sequence read, Y may be used to indicate that either pyrimidine nucleobase – C, T, or U – can be substituted at the indicated position.
Sources: en.wikipedia.org
== Structure == There are three types of muscle tissue in vertebrates: skeletal, cardiac, and smooth. Skeletal and cardiac muscle are types of striated muscle tissue. Smooth muscle is non-striated. There are three types of muscle tissue in invertebrates that are based on their pattern of striation: transversely striated, obliquely striated, and smooth muscle. In arthropods there is no smooth muscle. The transversely striated type is the most similar to the skeletal muscle in vertebrates. Vertebrate skeletal muscle tissue is an elongated, striated muscle tissue, with the fibres ranging from a few millimeters to several inches in length and from 10 to 100 micrometers in width. Skeletal striated muscle tissue is arranged in regular, parallel bundles of myofibrils, which contain many contractile units known as sarcomeres, which give the tissue its striated (striped) appearance. Skeletal muscle is voluntary muscle, anchored by tendons or sometimes by aponeuroses to bones, and is used to affect skeletal movement such as locomotion and to maintain posture. Postural control is generally maintained as an unconscious reflex, but the responsible muscles can also react to conscious control. The body mass of an average adult man is made up of 42% of skeletal muscle, and an average adult woman is made up of 36%. Cardiac muscle tissue is found only in the walls of the heart as myocardium, and it is an involuntary muscle controlled by the autonomic nervous system. Cardiac muscle tissue is striated like skeletal muscle, containing sarcomeres in highly regular arrangements of bundles.
These concerns are further exacerbated by the lack of transparency around steroid use, since many influencers either avoid clarifying whether they are “natural” bodybuilders or outright deny accusations of being “enhanced.” This blurs the line between what can be achieved naturally and what requires anabolic steroids. The issue is not limited to young people; adult lifters also face distorted body image from the content they consume, which can lead to an unhealthy relationship with nutrition and exercise. In some cases, this may contribute to mental health challenges such as body dysmorphia or eating disorders. Recently, however, more influencers have begun to open up about their steroid use and advocate for greater transparency online. This shift has sparked ongoing debates about the risks of anabolic steroids. Many see this as a positive development, as it helps raise awareness and educates audiences about the effects, uses, and dangers of these substances. Another widely discussed topic is mental health within bodybuilding, as the psychological challenges mentioned above can affect hobby lifters of all ages and backgrounds.
Spotlight Innovation Inc. (OTCQB: STLT) [STATUS CLOSED] was an American pharmaceutical holding company. The company maintained two subsidiaries: Caretta Therapeutics, Inc. and Celtic Biotech Iowa, Inc. Spotlight Innovation Inc. is based in Urbandale, Iowa and was publicly traded on the OTCQB marketplace under the stock ticker symbol, STLT.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.